Advanced search×

Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species

Bioorg Med Chem 18(6):7 (2010) PMID 20185316

There are many of pathogen parasite species with different susceptibility profile to antiparasitic drugs. Unfortunately, almost QSAR models predict the biological activity of drugs against only one parasite species. Consequently, predicting the probability with which a drug is active against different species with a single unify model is a goal of the major importance. In so doing, we use Markov Chains theory to calculate new multi-target spectral moments to fit a QSAR model that predict by the first time a mt-QSAR model for 500 drugs tested in the literature against 16 parasite species and other 207 drugs no tested in the literature using spectral moments. The data was processed by linear discriminant analysis (LDA) classifying drugs as active or non-active against the different tested parasite species. The model correctly classifies 311 out of 358 active compounds (86.9%) and 2328 out of 2577 non-active compounds (90.3%) in training series. Overall training performance was 89.9%. Validation of the model was carried out by means of external predicting series. In these series the model classified correctly 157 out 190, 82.6% of antiparasitic compounds and 1151 out of 1277 non-active compounds (90.1%). Overall predictability performance was 89.2%. In addition we developed four types of non Linear Artificial neural networks (ANN) and we compared with the mt-QSAR model. The improved ANN model had an overall training performance was 87%. The present work report the first attempts to calculate within a unify framework probabilities of antiparasitic action of drugs against different parasite species based on spectral moment analysis.

DOI: 10.1016/j.bmc.2010.01.068
Version: za2963e q8za4 q8zbb q8zca q8zdb q8ze9 q8zf3 q8zge

Similar articles you may find interesting…

  1. Thiolactomycin inhibits d-aspartate oxidase: A novel approach to probing the active site environment

    Biochimie 92(10):8 (2010) PMID 20603179

    We discovered several compounds that inhibited the activity of mouse DDO, and one of the compounds identified, thiolactomycin (TLM), was then characterized and evaluated as a novel DDO inhibitor. TLM reversibly inhibited the activity of mouse DDO with a mixed type of inhibition more efficiently than...
  2. Slow Onset Inhibition of Bacterial -Ketoacyl-acyl Carrier Protein Synthases by Thiolactomycin

    J Biol Chem 285(9):6161-6169 (2010) PMID 20018879

    Thiolactomycin (TLM), a natural product thiolactone antibiotic produced by species of Nocardia and Streptomyces is an inhibitor of the beta-ketoacyl-ACP synthase (KAS) enzymes in the bacterial fatty acid synthase pathway. Using enzyme kinetics and direct binding studies TLM has been...
  3. Analogues of thiolactomycin as potential antimalarial agents.

    J Med Chem 48(19):5932-41 (2005) PMID 16161997

    We conclude that pfKASIII is not the primary target of TLM analogues. Some of the analogues also inhibited the growth of the parasitic protozoa Trypanosoma cruzi, T. brucei, and Leishmania donovani....